Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial

When will the US government shutdown end? How will Starbucks union talks impact operations? Why is Tesla losing its Model Y manager? What caused Pfizer to acquire Metsera? How does the new Visa-Mastercard fee deal affect retailers? Why did Nvidia stock drop amid AI fears? What are the effects of FAA grounding MD-11 jets?

Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial

merck.com/news/mercks-enlicitide-decanoate-an-investigational-oral-pcsk9-inhibitor-significantly-reduced-ldl-c-in-phase-3-coralreef-lipids-trial

Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial
November 8, 2025 2:30 pm EST
Enlicitide, designed to deliver antibody-like efficacy, has the potential to be the first approved oral PCSK9 inhibitor to…

This story appeared on merck.com, 2025-11-09 07:03:13.651000.